Literature DB >> 17606754

HER2 status in breast cancer--an example of pharmacogenetic testing.

Mark Kroese1, Ron L Zimmern, Sarah E Pinder.   

Abstract

The development of new drugs and associated pharmacogenetic tests will provide an increasing number of challenges to health care systems. In particular, how to evaluate their benefits, prioritize for commissioning purposes and implement a service to provide them in a timely manner. This paper presents an overview of HER2 testing for trastuzumab (Herceptin) treatment in breast cancer cases. Immunohistochemistry and fluorescence in situ hybridization laboratory techniques are described and their HER2 testing performances are compared. Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17606754      PMCID： PMC1905880          DOI： 10.1177/014107680710000715

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


  19 in total

1.  Best Practice No 176: Updated recommendations for HER2 testing in the UK.

Authors:  I O Ellis; J Bartlett; M Dowsett; S Humphreys; B Jasani; K Miller; S E Pinder; A Rhodes; R Walker
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

2.  Herceptin and early breast cancer: a moment for caution.

Authors: 
Journal:  Lancet       Date:  2005-11-12       Impact factor: 79.321

3.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

Authors:  G Pauletti; S Dandekar; H Rong; L Ramos; H Peng; R Seshadri; D J Slamon
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

4.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

Review 5.  Current perspectives on HER2 testing: a review of national testing guidelines.

Authors:  Michael Bilous; Mitch Dowsett; Wedad Hanna; Jorma Isola; Annette Lebeau; Aberlardo Moreno; Frédérique Penault-Llorca; Josef Rüschoff; Gorana Tomasic; Marc van de Vijver
Journal:  Mod Pathol       Date:  2003-02       Impact factor: 7.842

Review 6.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

Authors:  Jeffrey S Ross; Jonathan A Fletcher; Gerald P Linette; James Stec; Edward Clark; Mark Ayers; W Fraser Symmans; Lajos Pusztai; Kenneth J Bloom
Journal:  Oncologist       Date:  2003

7.  HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

Authors:  Elena B Elkin; Milton C Weinstein; Eric P Winer; Karen M Kuntz; Stuart J Schnitt; Jane C Weeks
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

8.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

Authors:  M Dowsett; J Bartlett; I O Ellis; J Salter; M Hills; E Mallon; A D Watters; T Cooke; C Paish; P M Wencyk; S E Pinder
Journal:  J Pathol       Date:  2003-04       Impact factor: 7.996

Review 9.  The clinical evaluation of HER-2 status: which test to use?

Authors:  John Bartlett; Elizabeth Mallon; Tim Cooke
Journal:  J Pathol       Date:  2003-04       Impact factor: 7.996

10.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.

Authors:  Anthony Rhodes; Bharat Jasani; Elizabeth Anderson; Andrew R Dodson; André J Balaton
Journal:  Am J Clin Pathol       Date:  2002-09       Impact factor: 2.493
View more
  7 in total

1.  The prospect of genome-guided preventive medicine: a need and opportunity for genetic counselors.

Authors:  Julianne M O'Daniel
Journal:  J Genet Couns       Date:  2010-05-04       Impact factor: 2.537

Review 2.  Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.

Authors:  Patricia R Blank; Konstantin J Dedes; Thomas D Szucs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  HER2: biology, detection, and clinical implications.

Authors:  Carolina Gutierrez; Rachel Schiff
Journal:  Arch Pathol Lab Med       Date:  2011-01       Impact factor: 5.534

4.  Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells.

Authors:  Neil Kumar; Raffi Afeyan; Hyung-Do Kim; Douglas A Lauffenburger
Journal:  Mol Pharmacol       Date:  2008-03-18       Impact factor: 4.436

Review 5.  Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies.

Authors:  Mohamed I Nounou; Fatema ElAmrawy; Nada Ahmed; Kamilia Abdelraouf; Satyanarayana Goda; Hussaini Syed-Sha-Qhattal
Journal:  Breast Cancer (Auckl)       Date:  2015-09-27

6.  Impact of genetic polymorphisms on clinical response to antithrombotics.

Authors:  Kena J Lanham; Julie H Oestreich; Steven P Dunn; Steven R Steinhubl
Journal:  Pharmgenomics Pers Med       Date:  2010-06-18

Review 7.  Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Authors:  Young Kwang Chae; Ayush Arya; Lauren Chiec; Hiral Shah; Ari Rosenberg; Sandip Patel; Kirtee Raparia; Jaehyuk Choi; Derek A Wainwright; Victoria Villaflor; Massimo Cristofanilli; Francis Giles
Journal:  Oncotarget       Date:  2017-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.